89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
89bio, Inc. (ETNB)
Last 89bio, inc. earnings: 3/18 04:05 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it will host a key opinion leader (KOL) event of pegozafermin’s opportunity in advanced metabolic dysfunction-associated steatohepatitis (MASH) on Thursday, May 16, 2024 at 10:00am ET. The webinar will feature a presentation from expert hepatologist, Arun Sanyal, M.D., Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, Virginia Commonwealth University, who will discuss the unmet need and current treatment landscape for advanced MASH patients with fibrosis and compensated cirrhosis. The company will give an overview of the ENLIGHTEN-Cirrhosis trial and the broad commercial opportunity for pegozafermin in advanced MASH. A live question and answer session will follow the formal presentati
Show less
Read more
Impact Snapshot
Event Time:
ETNB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETNB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETNB alerts
High impacting 89bio, Inc. news events
Weekly update
A roundup of the hottest topics
ETNB
News
- 89bio, Inc. (NASDAQ: ETNB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $29.00 price target on the stock.MarketBeat
- 89bio, Inc. (NASDAQ: ETNB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $29.00 price target on the stock.MarketBeat
- 89bio, Inc. (NASDAQ: ETNB) had its price target lowered by analysts at Evercore ISI from $37.00 to $33.00. They now have an "outperform" rating on the stock.MarketBeat
- 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis [Yahoo! Finance]Yahoo! Finance
- 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated CirrhosisGlobeNewswire
ETNB
Earnings
- 5/9/24 - Miss
ETNB
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/3/24 - Form 4
- ETNB's page on the SEC website